{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T23:59:45Z","timestamp":1789516785794,"version":"build-2803163510"},"reference-count":106,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Psychiatry"],"DOI":"10.1038\/s41398-025-03654-3","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:31:52Z","timestamp":1761895912000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Psychedelics and ketamine\/esketamine in depressive disorders: biological mechanisms and associated neuroimaging and clinical changes"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6808-3960","authenticated-orcid":false,"given":"Giacomo","family":"d\u2019Andrea","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Chiappini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Ciavoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolando","family":"Tucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Martino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco Maria","family":"Semeraro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Di Battista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Mosca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2431-0460","authenticated-orcid":false,"given":"Andrea","family":"Miuli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Di Carlo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirella","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilberto","family":"Di Petta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9647-0853","authenticated-orcid":false,"given":"Michele","family":"Fornaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4164-3040","authenticated-orcid":false,"given":"Mauro","family":"Pettorruso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0710-2574","authenticated-orcid":false,"given":"Stefano L.","family":"Sensi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Martinotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,31]]},"reference":[{"key":"3654_CR1","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1002\/wps.20771","volume":"19","author":"M Maj","year":"2020","unstructured":"Maj M, Stein DJ, Parker G, Zimmerman M, Fava GA, De Hert M, et al. The clinical characterization of the adult patient with depression aimed at personalization of management. World Psychiatry. 2020;19:269\u201393. https:\/\/doi.org\/10.1002\/wps.20771.","journal-title":"World Psychiatry"},{"key":"3654_CR2","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1002\/wps.20989","volume":"21","author":"MB First","year":"2022","unstructured":"First MB, Yousif LH, Clarke DE, Wang PS, Gogtay N, Appelbaum PS. DSM-5-TR: overview of what\u2019s new and what\u2019s changed. World Psychiatry. 2022;21:218\u20139. https:\/\/doi.org\/10.1002\/wps.20989.","journal-title":"World Psychiatry"},{"key":"3654_CR3","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1177\/0706743716659417","volume":"61","author":"SH Kennedy","year":"2016","unstructured":"Kennedy SH, Lam RW, McIntyre RS, Tourjman SV, Bhat V, Blier P, et al. Canadian network for mood and anxiety treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 3. pharmacological treatments. Can J Psychiatry. 2016;61:540\u201360. https:\/\/doi.org\/10.1177\/0706743716659417.","journal-title":"Can J Psychiatry"},{"key":"3654_CR4","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.jad.2021.12.134","volume":"302","author":"NA Nunez","year":"2022","unstructured":"Nunez NA, Joseph B, Pahwa M, Kumar R, Resendez MG, Prokop LJ, et al. Augmentation strategies for treatment resistant major depression: a systematic review and network meta-analysis. J Affect Disord. 2022;302:385\u2013400. https:\/\/doi.org\/10.1016\/j.jad.2021.12.134.","journal-title":"J Affect Disord"},{"key":"3654_CR5","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1002\/wps.21120","volume":"22","author":"RS McIntyre","year":"2023","unstructured":"McIntyre RS, Alsuwaidan M, Baune BT, Berk M, Demyttenaere K, Goldberg JF, et al. Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions. World Psychiatry. 2023;22:394\u2013412. https:\/\/doi.org\/10.1002\/wps.21120.","journal-title":"World Psychiatry"},{"key":"3654_CR6","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s40263-021-00877-y","volume":"36","author":"S Ling","year":"2022","unstructured":"Ling S, Ceban F, Lui LMW, Lee Y, Teopiz KM, Rodrigues NB, et al. Molecular mechanisms of psilocybin and implications for the treatment of depression. CNS Drugs. 2022;36:17\u201330. https:\/\/doi.org\/10.1007\/s40263-021-00877-y.","journal-title":"CNS Drugs"},{"key":"3654_CR7","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.euroneuro.2023.02.010","volume":"70","author":"G D\u2019Andrea","year":"2023","unstructured":"D\u2019Andrea G, Pettorruso M, Lorenzo GD, Mancusi G, McIntyre RS, Martinotti G. Rethinking ketamine and esketamine action: Are they antidepressants with mood-stabilizing properties?. Eur Neuropsychopharmacol. 2023;70:49\u201355. https:\/\/doi.org\/10.1016\/j.euroneuro.2023.02.010.","journal-title":"Eur Neuropsychopharmacol"},{"key":"3654_CR8","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1038\/s41593-023-01316-5","volume":"26","author":"R","year":"2023","unstructured":"R Moliner, Girych M, Brunello CA, Kovaleva V, Biojone C, Enkavi G, et al. Psychedelics promote plasticity by directly binding to BDNF receptor TrkB. Nat Neurosci. 2023;26:1032\u201341. https:\/\/doi.org\/10.1038\/s41593-023-01316-5.","journal-title":"Nat Neurosci"},{"key":"3654_CR9","doi-asserted-by":"publisher","first-page":"856","DOI":"10.3390\/brainsci11070856","volume":"11","author":"G Martinotti","year":"2021","unstructured":"Martinotti G, Chiappini S, Pettorruso M, Mosca A, Miuli A, Di Carlo F, et al. Therapeutic potentials of ketamine and esketamine in obsessive\u2013compulsive disorder (Ocd), substance use disorders (sud) and eating disorders (ed): a review of the current literature. Brain Sci. 2021;11:856. https:\/\/doi.org\/10.3390\/brainsci11070856.","journal-title":"Brain Sci"},{"key":"3654_CR10","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.jpsychires.2022.04.037","volume":"151","author":"Y Alnefeesi","year":"2022","unstructured":"Alnefeesi Y, Chen-Li D, Krane E, Jawad MY, Rodrigues NB, Ceban F, et al. Real-world effectiveness of ketamine in treatment-resistant depression: a systematic review & meta-analysis. J Psychiatr Res. 2022;151:693\u2013709. https:\/\/doi.org\/10.1016\/j.jpsychires.2022.04.037.","journal-title":"J Psychiatr Res"},{"key":"3654_CR11","doi-asserted-by":"publisher","first-page":"909","DOI":"10.3390\/brainsci13060909","volume":"13","author":"MY Jawad","year":"2023","unstructured":"Jawad MY, Qasim S, Ni M, Guo Z, Di Vincenzo JD, d\u2019Andrea G, et al. The role of ketamine in the treatment of bipolar depression: a scoping review. Brain Sci. 2023;13:909. https:\/\/doi.org\/10.3390\/brainsci13060909.","journal-title":"Brain Sci"},{"key":"3654_CR12","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.jad.2022.09.043","volume":"319","author":"G Martinotti","year":"2022","unstructured":"Martinotti G, Vita A, Fagiolini A, Maina G, Bertolino A, Dell\u2019Osso B, et al. Real-world experience of esketamine use to manage treatment-resistant depression: A multicentric study on safety and effectiveness (REAL-ESK study). J Affect Disord. 2022;319:646\u201354. https:\/\/doi.org\/10.1016\/j.jad.2022.09.043.","journal-title":"J Affect Disord"},{"key":"3654_CR13","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1176\/appi.ajp.2020.20081251","volume":"178","author":"RS McIntyre","year":"2021","unstructured":"McIntyre RS, Rosenblat JD, Nemeroff CB, Sanacora G, Murrough JW, Berk M, et al. Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: An international expert opinion on the available evidence and implementation. American J Psychiatry. 2021;178:383\u201399. https:\/\/doi.org\/10.1176\/appi.ajp.2020.20081251.","journal-title":"American J Psychiatry"},{"key":"3654_CR14","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/j.jagp.2023.06.016","volume":"31","author":"G d\u2019Andrea","year":"2023","unstructured":"d\u2019Andrea G, Chiappini S, McIntyre RS, Stefanelli G, Carullo R, Andriola I, et al. Investigating the effectiveness and tolerability of intranasal esketamine among older adults with treatment-resistant depression (TRD): a post-hoc analysis from the REAL-ESK study group. Am J Geriatr Psychiatry. 2023;31:1032\u201341. https:\/\/doi.org\/10.1016\/j.jagp.2023.06.016.","journal-title":"Am J Geriatr Psychiatry"},{"key":"3654_CR15","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.euroneuro.2023.04.011","volume":"74","author":"S Chiappini","year":"2023","unstructured":"Chiappini S, d\u2019Andrea G, De Filippis S, Di Nicola M, Andriola I, Bassetti R, et al. Esketamine in treatment-resistant depression patients comorbid with substance-use disorder: a viewpoint on its safety and effectiveness in a subsample of patients from the REAL-ESK study. Eur Neuropsychopharmacol. 2023;74:15\u201321. https:\/\/doi.org\/10.1016\/j.euroneuro.2023.04.011.","journal-title":"Eur Neuropsychopharmacol"},{"key":"3654_CR16","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/bdi.13296","volume":"25","author":"G Martinotti","year":"2023","unstructured":"Martinotti G, Dell\u2019Osso B, Di Lorenzo G, Maina G, Bertolino A, Clerici M, et al. Treating bipolar depression with esketamine: safety and effectiveness data from a naturalistic multicentric study on esketamine in bipolar versus unipolar treatment-resistant depression. Bipolar Disord. 2023;25:233\u201344. https:\/\/doi.org\/10.1111\/bdi.13296.","journal-title":"Bipolar Disord"},{"key":"3654_CR17","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.jad.2022.12.021","volume":"323","author":"S Meshkat","year":"2023","unstructured":"Meshkat S, Ho RC, Cao B, Teopiz KM, Rosenblat JD, Rhee TG, et al. Biomarkers of ketamine\u2019s antidepressant effect: an umbrella review. J Affect Disord. 2023;323:598\u2013606. https:\/\/doi.org\/10.1016\/j.jad.2022.12.021.","journal-title":"J Affect Disord"},{"key":"3654_CR18","doi-asserted-by":"publisher","first-page":"115378","DOI":"10.1016\/j.psychres.2023.115378","volume":"327","author":"M Pettorruso","year":"2023","unstructured":"Pettorruso M, Guidotti R, d\u2019Andrea G, De Risio L, D\u2019Andrea A, Chiappini S, et al. Predicting outcome with intranasal esketamine treatment: a machine-learning, three-month study in treatment-resistant depression (ESK-LEARNING). Psychiatry Res. 2023;327:115378. https:\/\/doi.org\/10.1016\/j.psychres.2023.115378.","journal-title":"Psychiatry Res"},{"key":"3654_CR19","doi-asserted-by":"publisher","unstructured":"Carhart-Harris RL, Goodwin GM. The therapeutic potential of psychedelic drugs: past, present, and future. Neuropsychopharmacology. 2017;42:2105\u201313. https:\/\/doi.org\/10.1038\/npp.2017.84.","DOI":"10.1038\/npp.2017.84"},{"key":"3654_CR20","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.neuropharm.2017.12.040","volume":"142","author":"JJH Rucker","year":"2018","unstructured":"Rucker JJH, Iliff J, Nutt DJ. Psychiatry & the psychedelic drugs. past, present & future. Neuropharmacology. 2018;142:200\u201318. https:\/\/doi.org\/10.1016\/j.neuropharm.2017.12.040.","journal-title":"Neuropharmacology"},{"key":"3654_CR21","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1177\/02698811211003495","volume":"35","author":"JJ Rucker","year":"2021","unstructured":"Rucker JJ, Seth P. Psychedelics: old drugs, new trips. J Psychopharmacol. 2021;35:316\u20138. https:\/\/doi.org\/10.1177\/02698811211003495.","journal-title":"J Psychopharmacol"},{"key":"3654_CR22","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1080\/14737175.2020.1826931","volume":"20","author":"H Gill","year":"2020","unstructured":"Gill H, Gill B, Chen-Li D, El-Halabi S, Rodrigues NB, Cha DS, et al. The emerging role of psilocybin and MDMA in the treatment of mental illness. Expert Rev Neurother. 2020;20:1263\u201373. https:\/\/doi.org\/10.1080\/14737175.2020.1826931.","journal-title":"Expert Rev Neurother"},{"key":"3654_CR23","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/acps.13249","volume":"143","author":"KAA Andersen","year":"2021","unstructured":"Andersen KAA, Carhart-Harris R, Nutt DJ, Erritzoe D. Therapeutic effects of classic serotonergic psychedelics: a systematic review of modern-era clinical studies. Acta Psychiatr Scand. 2021;143:101\u201318. https:\/\/doi.org\/10.1111\/acps.13249.","journal-title":"Acta Psychiatr Scand"},{"key":"3654_CR24","doi-asserted-by":"publisher","DOI":"10.2174\/1570159X21666221017085612","author":"A Mosca","year":"2022","unstructured":"Mosca A, Chiappini S, Miuli A, Mancusi G, Santovito MC, Di Carlo F, et al. Ibogaine\/noribogaine in the treatment of substance use disorders: a systematic review of the current literature. Curr Neuropharmacol. 2022. https:\/\/doi.org\/10.2174\/1570159X21666221017085612.","journal-title":"Curr Neuropharmacol"},{"key":"3654_CR25","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.cell.2020.03.020","volume":"181","author":"D Nutt","year":"2020","unstructured":"Nutt D, Erritzoe D, Carhart-Harris R. Psychedelic psychiatry\u2019s brave new world. Cell. 2020;181:24\u201328. https:\/\/doi.org\/10.1016\/j.cell.2020.03.020.","journal-title":"Cell"},{"key":"3654_CR26","doi-asserted-by":"publisher","first-page":"841648","DOI":"10.3389\/fphar.2022.841648","volume":"13","author":"DE McCulloch","year":"2022","unstructured":"McCulloch DE, Grzywacz MZ, Madsen MK, Jensen PS, Ozenne B, Armand S, et al. Psilocybin-induced mystical-type experiences are related to persisting positive effects: a quantitative and qualitative report. Front Pharm. 2022;13:841648. https:\/\/doi.org\/10.3389\/fphar.2022.841648.","journal-title":"Front Pharm"},{"key":"3654_CR27","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1111\/cns.12835","volume":"24","author":"FF Zhang","year":"2018","unstructured":"Zhang FF, Peng W, Sweeney JA, Jia ZY, Gong QY. Brain structure alterations in depression: psychoradiological evidence. CNS Neurosci Therapeutics. 2018;24:994\u20131003. https:\/\/doi.org\/10.1111\/cns.12835.","journal-title":"CNS Neurosci Therapeutics"},{"key":"3654_CR28","doi-asserted-by":"publisher","first-page":"361","DOI":"10.47162\/RJME.61.2.06","volume":"61","author":"SC Trifu","year":"2020","unstructured":"Trifu SC, Trifu AC, Alua\u015f E, T\u0103taru MA, Costea RV. Brain changes in depression. Rom J Morphol Embryol. 2020;61:361\u201370. https:\/\/doi.org\/10.47162\/RJME.61.2.06.","journal-title":"Rom J Morphol Embryol"},{"key":"3654_CR29","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1111\/cns.12998","volume":"24","author":"BJ Li","year":"2018","unstructured":"Li BJ, Friston K, Mody M, Wang HN, Lu HB, Hu DW. A brain network model for depression: From symptom understanding to disease intervention. CNS Neurosci Therapeutics. 2018;24:1004\u201319. https:\/\/doi.org\/10.1111\/cns.12998.","journal-title":"CNS Neurosci Therapeutics"},{"key":"3654_CR30","doi-asserted-by":"publisher","first-page":"519","DOI":"10.3390\/brainsci10080519","volume":"10","author":"M Pettorruso","year":"2020","unstructured":"Pettorruso M, d\u2019Andrea G, Martinotti G, Cocciolillo F, Miuli A, Di Muzio I, et al. Hopelessness, dissociative symptoms, and suicide risk in major depressive disorder: clinical and biological correlates. Brain Sci. 2020;10:519. https:\/\/doi.org\/10.3390\/brainsci10080519.","journal-title":"Brain Sci"},{"key":"3654_CR31","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1176\/appi.focus.16206","volume":"16","author":"R Strawbridge","year":"2018","unstructured":"Strawbridge R, Young AH, Cleare AJ. Biomarkers for depression: recent insights, current challenges and future prospects. Focus (Am Psychiatr Publ). 2018;16:194\u2013209. https:\/\/doi.org\/10.1176\/appi.focus.16206.","journal-title":"Focus (Am Psychiatr Publ)"},{"key":"3654_CR32","doi-asserted-by":"publisher","first-page":"3296","DOI":"10.1093\/brain\/aww255","volume":"139","author":"W Cheng","year":"2016","unstructured":"Cheng W, Rolls ET, Qiu J, Liu W, Tang Y, Huang CC, et al. Medial reward and lateral non-reward orbitofrontal cortex circuits change in opposite directions in depression. Brain. 2016;139:3296\u2013309. https:\/\/doi.org\/10.1093\/brain\/aww255.","journal-title":"Brain"},{"key":"3654_CR33","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1017\/S0033291714002001","volume":"45","author":"CG Davey","year":"2015","unstructured":"Davey CG, Whittle S, Harrison BJ, Simmons JG, Byrne ML, Schwartz OS, et al. Functional brain-imaging correlates of negative affectivity and the onset of first-episode depression. Psychol Med. 2015;45:1001\u20139. https:\/\/doi.org\/10.1017\/S0033291714002001.","journal-title":"Psychol Med"},{"key":"3654_CR34","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.biopsych.2011.10.035","volume":"71","author":"X Zhu","year":"2012","unstructured":"Zhu X, Wang X, Xiao J, Liao J, Zhong M, Wang W, et al. Evidence of a dissociation pattern in resting-state default mode network connectivity in first-episode, treatment-naive major depression patients. Biol Psychiatry. 2012;71:611\u20137. https:\/\/doi.org\/10.1016\/j.biopsych.2011.10.035.","journal-title":"Biol Psychiatry"},{"key":"3654_CR35","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1111\/j.1469-7610.2012.02552.x","volume":"53","author":"MS Gaffrey","year":"2012","unstructured":"Gaffrey MS, Luby JL, Botteron K, Repov\u0161 G, Barch DM. Default mode network connectivity in children with a history of preschool onset depression. J Child Psychol Psychiatry. 2012;53:964\u201372. https:\/\/doi.org\/10.1111\/j.1469-7610.2012.02552.x.","journal-title":"J Child Psychol Psychiatry"},{"key":"3654_CR36","doi-asserted-by":"publisher","first-page":"2554","DOI":"10.1093\/brain\/aww157","volume":"139","author":"A Manelis","year":"2016","unstructured":"Manelis A, Almeida JRC, Stiffler R, Lockovich JC, Aslam HA, Phillips ML. Anticipation-related brain connectivity in bipolar and unipolar depression: a graph theory approach. Brain. 2016;139:2554\u201366. https:\/\/doi.org\/10.1093\/brain\/aww157.","journal-title":"Brain"},{"key":"3654_CR37","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1176\/appi.ajp.2015.15020162","volume":"173","author":"WK Simmons","year":"2016","unstructured":"Simmons WK, Burrows K, Avery JA, Kerr KL, Bodurka J, Savage CR, et al. Depression-related increases and decreases in appetite: dissociable patterns of aberrant activity in reward and interoceptive neurocircuitry. Am J Psychiatry. 2016;173:418\u201328. https:\/\/doi.org\/10.1176\/appi.ajp.2015.15020162.","journal-title":"Am J Psychiatry"},{"key":"3654_CR38","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1097\/JGP.0b013e31817b60af","volume":"17","author":"HJ Aizenstein","year":"2009","unstructured":"Aizenstein HJ, Butters MA, Wu M, Mazurkewicz LM, Stenger VA, Gianaros PJ, et al. Altered functioning of the executive control circuit in late-life depression: episodic and persistent phenomena. Am J Geriatr Psychiatry. 2009;17:30\u201342. https:\/\/doi.org\/10.1097\/JGP.0b013e31817b60af.","journal-title":"Am J Geriatr Psychiatry"},{"key":"3654_CR39","doi-asserted-by":"publisher","first-page":"2939","DOI":"10.1002\/hbm.23564","volume":"38","author":"JP Stange","year":"2017","unstructured":"Stange JP, Bessette KL, Jenkins LM, Peters AT, Feldhaus C, Crane NA, et al. Attenuated intrinsic connectivity within cognitive control network among individuals with remitted depression: temporal stability and association with negative cognitive styles. Hum Brain Mapp. 2017;38:2939\u201354. https:\/\/doi.org\/10.1002\/hbm.23564.","journal-title":"Hum Brain Mapp"},{"key":"3654_CR40","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"key":"3654_CR41","doi-asserted-by":"publisher","first-page":"g7647","DOI":"10.1186\/2046-4053-4-1","volume":"350","author":"D Moher","year":"2015","unstructured":"Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015;350:g7647. https:\/\/doi.org\/10.1186\/2046-4053-4-1.","journal-title":"BMJ"},{"key":"3654_CR42","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1177\/0269881120928203","volume":"35","author":"AV Roy","year":"2021","unstructured":"Roy AV, Thai M, Klimes-Dougan B, Westlund Schreiner M, Mueller BA, Albott CS, et al. Brain entropy and neurotrophic molecular markers accompanying clinical improvement after ketamine: Preliminary evidence in adolescents with treatment-resistant depression. Journal Psychopharmacol (Oxf, Engl). 2021;35:168\u201377. https:\/\/doi.org\/10.1177\/0269881120928203.","journal-title":"Journal Psychopharmacol (Oxf, Engl)"},{"key":"3654_CR43","doi-asserted-by":"publisher","unstructured":"Abdallah CG, Dutta A, Averill CL, McKie S, Akiki TJ, Averill LA, et al. Ketamine, but Not the NMDAR antagonist lanicemine, increases prefrontal global connectivity in depressed patients, Chronic stress (Thousand Oaks, Calif.), vol. 2, 2018. https:\/\/doi.org\/10.1177\/2470547018796102","DOI":"10.1177\/2470547018796102"},{"key":"3654_CR44","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1038\/s41386-018-0057-1","volume":"43","author":"JW Evans","year":"2018","unstructured":"Evans JW, Lally N, An L, Li N, Nugent AC, Banerjee D, et al. 7T 1H-MRS in major depressive disorder: a Ketamine Treatment Study. Neuropsychopharmacology. 2018;43:1908\u201314. https:\/\/doi.org\/10.1038\/s41386-018-0057-1. pp.","journal-title":"Neuropsychopharmacology"},{"key":"3654_CR45","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1038\/mp.2015.83","volume":"21","author":"MS Milak","year":"2016","unstructured":"Milak MS, Proper CJ, Mulhern ST, Parter AL, Kegeles LS, Ogden RT, et al. A pilot in vivo proton magnetic resonance spectroscopy study of amino acid neurotransmitter response to ketamine treatment of major depressive disorder. Mol Psychiatry. 2016;21:320\u20137. https:\/\/doi.org\/10.1038\/mp.2015.83.","journal-title":"Mol Psychiatry"},{"key":"3654_CR46","doi-asserted-by":"publisher","first-page":"e2013211","DOI":"10.1001\/jamanetworkopen.2020.13211","volume":"3","author":"MS Milak","year":"2020","unstructured":"Milak MS, Rashid R, Dong Z, Kegeles LS, Grunebaum MF, Ogden RT, et al. Assessment of relationship of ketamine dose with magnetic resonance spectroscopy of Glx and GABA responses in adults with major depression: a randomized clinical trial. JAMA Netw open. 2020;3:e2013211. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.13211.","journal-title":"JAMA Netw open"},{"key":"3654_CR47","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.pscychresns.2010.10.009","volume":"191","author":"GW Valentine","year":"2011","unstructured":"Valentine GW, Mason GF, Gomez R, Fasula M, Watzl J, Pittman B, et al. The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [(1)H]-MRS. Psychiatry Res. 2011;191:122\u20137. https:\/\/doi.org\/10.1016\/j.pscychresns.2010.10.009.","journal-title":"Psychiatry Res"},{"key":"3654_CR48","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1097\/JCP.0000000000000436","volume":"36","author":"RF Sanches","year":"2016","unstructured":"Sanches RF, de Lima Os\u00f3rio F, Dos Santos RG, Macedo LR, Maia-de-Oliveira JP, Wichert-Ana L, et al. Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a SPECT study. J Clin Psychopharmacol. 2016;36:77\u201381. https:\/\/doi.org\/10.1097\/JCP.0000000000000436.","journal-title":"J Clin Psychopharmacol"},{"key":"3654_CR49","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jpsychires.2014.07.027","volume":"58","author":"ED Ballard","year":"2014","unstructured":"Ballard ED, Ionescu DF, Vande Voort JL, Niciu MJ, Richards EM, Luckenbaugh DA, et al. Improvement in suicidal ideation after ketamine infusion: relationship to reductions in depression and anxiety. J Psychiatr Res. 2014;58:161\u20136. https:\/\/doi.org\/10.1016\/j.jpsychires.2014.07.027.","journal-title":"J Psychiatr Res"},{"key":"3654_CR50","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1016\/j.biopsych.2013.02.008","volume":"73","author":"PJ Carlson","year":"2013","unstructured":"Carlson PJ, Diazgranados N, Nugent AC, Ibrahim L, Luckenbaugh DA, Brutsche N, et al. Neural correlates of rapid antidepressant response to ketamine in treatment-resistant unipolar depression: a preliminary positron emission tomography study. Biol Psychiatry. 2013;73:1213\u201321. https:\/\/doi.org\/10.1016\/j.biopsych.2013.02.008.","journal-title":"Biol Psychiatry"},{"key":"3654_CR51","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.jad.2017.09.008","volume":"225","author":"MH Chen","year":"2018","unstructured":"Chen MH, Li CT, Lin WC, Hong CJ, Tu PC, Bai YM, et al. Persistent antidepressant effect of low-dose ketamine and activation in the supplementary motor area and anterior cingulate cortex in treatment-resistant depression: A randomized control study. J Affect Disord. 2018;225:709\u201314. https:\/\/doi.org\/10.1016\/j.jad.2017.09.008.","journal-title":"J Affect Disord"},{"key":"3654_CR52","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1038\/mp.2017.58","volume":"23","author":"I Esterlis","year":"2018","unstructured":"Esterlis I, DellaGioia N, Pietrzak RH, Matuskey D, Nabulsi N, Abdallah CG, et al. Ketamine-induced reduction in mGluR5 availability is associated with an antidepressant response: an [(11)C]ABP688 and PET imaging study in depression. Mol Psychiatry. 2018;23:824\u201332. https:\/\/doi.org\/10.1038\/mp.2017.58.","journal-title":"Mol Psychiatry"},{"key":"3654_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2014.105","volume":"4","author":"N Lally","year":"2014","unstructured":"Lally N, Nugent AC, Luckenbaugh DA, Ameli R, Roiser JP, Zarate CA. Anti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression. Transl Psychiatry. 2014;4:e469. https:\/\/doi.org\/10.1038\/tp.2014.105.","journal-title":"Transl Psychiatry"},{"key":"3654_CR54","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1177\/0269881114568041","volume":"29","author":"N Lally","year":"2015","unstructured":"Lally N, Nugent AC, Luckenbaugh DA, Niciu MJ, Roiser JP, Zarate CAJ. Neural correlates of change in major depressive disorder anhedonia following open-label ketamine. J Psychopharmacol. 2015;29:596\u2013607. https:\/\/doi.org\/10.1177\/0269881114568041.","journal-title":"J Psychopharmacol"},{"key":"3654_CR55","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1002\/hbm.23085","volume":"37","author":"CT Li","year":"2016","unstructured":"Li CT, Chen MH, Lin WC, Hong CJ, Yang BH, Liu RS, et al. The effects of low-dose ketamine on the prefrontal cortex and amygdala in treatment-resistant depression: A randomized controlled study. Hum Brain Mapp. 2016;37:1080\u201390. https:\/\/doi.org\/10.1002\/hbm.23085.","journal-title":"Hum Brain Mapp"},{"key":"3654_CR56","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/bdi.12118","volume":"16","author":"AC Nugent","year":"2014","unstructured":"Nugent AC, Diazgranados N, Carlson PJ, Ibrahim L, Luckenbaugh DA, Brutsche N, et al. Neural correlates of rapid antidepressant response to ketamine in bipolar disorder. Bipolar Disord. 2014;16:119\u201328. https:\/\/doi.org\/10.1111\/bdi.12118.","journal-title":"Bipolar Disord"},{"key":"3654_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-020-0844-4","volume":"10","author":"M Tiger","year":"2020","unstructured":"Tiger M, Veldman ER, Ekman C-J, Halldin C, Svenningsson P, Lundberg J. A randomized placebo-controlled PET study of ketamine\u00b4s effect on serotonin(1B) receptor binding in patients with SSRI-resistant depression. Transl Psychiatry. 2020;10:159. https:\/\/doi.org\/10.1038\/s41398-020-0844-4.","journal-title":"Transl Psychiatry"},{"key":"3654_CR58","doi-asserted-by":"publisher","first-page":"247054702098068","DOI":"10.1177\/2470547020980681","volume":"4","author":"D Dai","year":"2020","unstructured":"Dai D, Lacadie CM, Holmes SE, Cool R, Anticevic A, Averill C, et al. Ketamine normalizes the structural alterations of inferior frontal gyrus in depression. Chronic stress (Thousand Oaks, Calif). 2020;4:2470547020980681 https:\/\/doi.org\/10.1177\/2470547020980681.","journal-title":"Chronic stress (Thousand Oaks, Calif)"},{"key":"3654_CR59","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.euroneuro.2020.11.017","volume":"43","author":"A Herrera-Melendez","year":"2021","unstructured":"Herrera-Melendez A, Stippl A, Aust S, Scheidegger M, Seifritz E, Heuser-Collier, et al. Gray matter volume of rostral anterior cingulate cortex predicts rapid antidepressant response to ketamine. Eur Neuropsychopharmacol. 2021;43:63\u201370. https:\/\/doi.org\/10.1016\/j.euroneuro.2020.11.017.","journal-title":"Eur Neuropsychopharmacol"},{"key":"3654_CR60","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-020-00947-7","volume":"10","author":"AK Sahib","year":"2020","unstructured":"Sahib AK, Loureiro JR, Vasavada MM, Kubicki A, Wade B, Joshi SH, et al. Modulation of inhibitory control networks relate to clinical response following ketamine therapy in major depression. Transl Psychiatry. 2020;10:260. https:\/\/doi.org\/10.1038\/s41398-020-00947-7.","journal-title":"Transl Psychiatry"},{"key":"3654_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-020-01122-8","volume":"10","author":"VJ Sydnor","year":"2020","unstructured":"Sydnor VJ, Lyall AE, Cetin-Karayumak S, Cheung JC, Felicione JM, Akeju O, et al. Studying pre-treatment and ketamine-induced changes in white matter microstructure in the context of ketamine\u2019s antidepressant effects. Transl Psychiatry. 2020;10:432. https:\/\/doi.org\/10.1038\/s41398-020-01122-8.","journal-title":"Transl Psychiatry"},{"key":"3654_CR62","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.bpsc.2020.06.015","volume":"6","author":"MM Vasavada","year":"2021","unstructured":"Vasavada MM, Loureiro J, Kubicki A, Sahib A, Wade B, Hellemann G, et al. Effects of serial ketamine infusions on corticolimbic functional connectivity in major depression. Biol Psychiatry. 2021;6:735\u201344. https:\/\/doi.org\/10.1016\/j.bpsc.2020.06.015.","journal-title":"Biol Psychiatry"},{"key":"3654_CR63","doi-asserted-by":"publisher","first-page":"e01674","DOI":"10.1002\/brb3.1674","volume":"10","author":"C Zhuo","year":"2020","unstructured":"Zhuo C, Ji F, Tian H, Wang L, Jia F, Jiang D, et al. Transient effects of multi-infusion ketamine augmentation on treatment-resistant depressive symptoms in patients with treatment-resistant bipolar depression - An open-label three-week pilot study. Brain Behav. 2020;10:e01674 https:\/\/doi.org\/10.1002\/brb3.1674.","journal-title":"Brain Behav"},{"key":"3654_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-13282-7","volume":"7","author":"RL Carhart-Harris","year":"2017","unstructured":"Carhart-Harris RL, Roseman L, Bolstridge M, Demetriou L, Pannekoek JN, Wall MB, et al. Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. Sci Rep. 2017;7:13187. https:\/\/doi.org\/10.1038\/s41598-017-13282-7.","journal-title":"Sci Rep."},{"key":"3654_CR65","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-021-01706-y","volume":"11","author":"MK Doss","year":"2021","unstructured":"Doss MK, Pova\u017ean M, Rosenberg MD, Sepeda ND, Davis AK, Finan PH, et al. Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder. Transl Psychiatry. 2021;11:574. https:\/\/doi.org\/10.1038\/s41398-021-01706-y.","journal-title":"Transl Psychiatry"},{"key":"3654_CR66","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1177\/0269881119895520","volume":"34","author":"LJ Mertens","year":"2020","unstructured":"Mertens LJ, Wall MB, Roseman L, Demetriou L, Nutt DJ, Carhart-Harris RL. Therapeutic mechanisms of psilocybin: Changes in amygdala and prefrontal functional connectivity during emotional processing after psilocybin for treatment-resistant depression. Journal Psychopharmacol. 2020;34:167\u201380. https:\/\/doi.org\/10.1177\/0269881119895520.","journal-title":"Journal Psychopharmacol"},{"key":"3654_CR67","doi-asserted-by":"publisher","first-page":"974","DOI":"10.3389\/fphar.2017.00974","volume":"8","author":"L Roseman","year":"2017","unstructured":"Roseman L, Nutt DJ, Carhart-Harris RL. Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression. Front Pharm. 2017;8:974. https:\/\/doi.org\/10.3389\/fphar.2017.00974.","journal-title":"Front Pharm"},{"key":"3654_CR68","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1038\/s41386-020-0624-0","volume":"45","author":"C Kraus","year":"2020","unstructured":"Kraus C, Mkrtchian A, Kadriu B, Nugent AC, Zarate CAJ, Evans JW. Evaluating global brain connectivity as an imaging marker for depression: influence of preprocessing strategies and placebo-controlled ketamine treatment. Neuropsychopharmacology. 2020;45:982\u20139. https:\/\/doi.org\/10.1038\/s41386-020-0624-0.","journal-title":"Neuropsychopharmacology"},{"key":"3654_CR69","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1097\/ALN.0000000000002667","volume":"130","author":"V Sterpenich","year":"2019","unstructured":"Sterpenich V, Vidal S, Hofmeister J, Michalopoulos G, Bancila V, Warrot D, et al. Increased reactivity of the mesolimbic reward system after ketamine injection in patients with treatment-resistant major depressive disorder. Anesthesiology. 2019;130:923\u201335. https:\/\/doi.org\/10.1097\/ALN.0000000000002667.","journal-title":"Anesthesiology"},{"key":"3654_CR70","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jad.2019.08.022","volume":"259","author":"MH Chen","year":"2019","unstructured":"Chen MH, Lin WC, Tu PC, Li CT, Bai YM, Tsai SJ, et al. Antidepressant and antisuicidal effects of ketamine on the functional connectivity of prefrontal cortex-related circuits in treatment-resistant depression: a double-blind, placebo-controlled, randomized, longitudinal resting fMRI study. J Affect Disord. 2019;259:15\u201320. https:\/\/doi.org\/10.1016\/j.jad.2019.08.022.","journal-title":"J Affect Disord"},{"key":"3654_CR71","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.npbr.2020.08.006","volume":"38","author":"S Gonzalez","year":"2020","unstructured":"Gonzalez S, Vasavada M, Njau S, Sahib AK, Espinoza R, Narr KL, et al. Acute changes in cerebral blood flow after single-infusion ketamine in major depression: a pilot study. Neurology, psychiatry, brain Res. 2020;38:5\u201311. https:\/\/doi.org\/10.1016\/j.npbr.2020.08.006.","journal-title":"Neurology, psychiatry, brain Res"},{"key":"3654_CR72","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1038\/s41386-019-0591-5","volume":"45","author":"LS Morris","year":"2020","unstructured":"Morris LS, Costi S, Tan A, Stern ER, Charney DS, Murrough JW. Ketamine normalizes subgenual cingulate cortex hyper-activity in depression. Neuropsychopharmacology. 2020;45:975\u201381. https:\/\/doi.org\/10.1038\/s41386-019-0591-5.","journal-title":"Neuropsychopharmacology"},{"key":"3654_CR73","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1093\/ijnp\/pyaa089","volume":"24","author":"AM Rivas-Grajales","year":"2021","unstructured":"Rivas-Grajales AM, Salas R, Robinson ME, Qi K, Murrough JW, Mathew SJ. Habenula connectivity and intravenous ketamine in treatment-resistant depression. international J Neuropsychopharmacol. 2021;24:383\u201391. https:\/\/doi.org\/10.1093\/ijnp\/pyaa089.","journal-title":"international J Neuropsychopharmacol"},{"key":"3654_CR74","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1007\/s00213-021-05762-6","volume":"238","author":"JS Siegel","year":"2021","unstructured":"Siegel JS, Palanca BJA, Ances BM, Kharasch ED, Schweiger JA, Yingling MD, et al. Prolonged ketamine infusion modulates limbic connectivity and induces sustained remission of treatment-resistant depression. Psychopharmacology (Berl). 2021;238:1157\u201369. https:\/\/doi.org\/10.1007\/s00213-021-05762-6.","journal-title":"Psychopharmacology (Berl)"},{"key":"3654_CR75","doi-asserted-by":"publisher","first-page":"102792","DOI":"10.1016\/j.nicl.2021.102792","volume":"32","author":"JRA Loureiro","year":"2021","unstructured":"Loureiro JRA, Sahib AK, Vasavada M, Leaver A, Kubicki A, Wade B, et al. Ketamine\u2019s modulation of cerebro-cerebellar circuitry during response inhibition in major depression. NeuroImage Clin. 2021;32:102792. https:\/\/doi.org\/10.1016\/j.nicl.2021.102792.","journal-title":"NeuroImage Clin"},{"key":"3654_CR76","doi-asserted-by":"publisher","first-page":"3292","DOI":"10.1038\/s41380-020-00878-1","volume":"26","author":"A Mkrtchian","year":"2021","unstructured":"Mkrtchian A, Evans JW, Kraus C, Yuan P, Kadriu B, Nugent AC, et al. Ketamine modulates fronto-striatal circuitry in depressed and healthy individuals. Mol Psychiatry. 2021;26:3292\u2013301. https:\/\/doi.org\/10.1038\/s41380-020-00878-1.","journal-title":"Mol Psychiatry"},{"key":"3654_CR77","doi-asserted-by":"publisher","first-page":"948729","DOI":"10.3389\/fpsyg.2022.948729","volume":"13","author":"A S\u00f8ndergaard","year":"2022","unstructured":"S\u00f8ndergaard A, Madsen MK, Ozenne B, Armand S, Knudsen GM, Fisher PM, et al. Lasting increases in trait mindfulness after psilocybin correlate positively with the mystical-type experience in healthy individuals. Front Psychol. 2022;13:948729. https:\/\/doi.org\/10.3389\/fpsyg.2022.948729.","journal-title":"Front Psychol"},{"key":"3654_CR78","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1038\/npp.2016.186","volume":"42","author":"CG Abdallah","year":"2017","unstructured":"Abdallah CG, Averill LA, Collins KA, Geha P, Schwartz J, Averill C, et al. Ketamine treatment and global brain connectivity in major depression. Neuropsychopharmacology. 2017;42:1210\u20139. https:\/\/doi.org\/10.1038\/npp.2016.186.","journal-title":"Neuropsychopharmacology"},{"key":"3654_CR79","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1002\/hbm.22241","volume":"35","author":"L Wang","year":"2014","unstructured":"Wang L, Dai Z, Peng H, Tan L, Ding Y, He Z, et al. Overlapping and segregated resting-state functional connectivity in patients with major depressive disorder with and without childhood neglect. Hum Brain Mapp. 2014;35:1154\u201366. https:\/\/doi.org\/10.1002\/hbm.22241.","journal-title":"Hum Brain Mapp"},{"key":"3654_CR80","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.biopsych.2015.02.020","volume":"78","author":"JP Hamilton","year":"2015","unstructured":"Hamilton JP, Farmer M, Fogelman P, Gotlib IH. Depressive rumination, the default-mode network, and the dark matter of clinical neuroscience. Biol Psychiatry. 2015;78:224\u201330. https:\/\/doi.org\/10.1016\/j.biopsych.2015.02.020.","journal-title":"Biol Psychiatry"},{"key":"3654_CR81","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.euroneuro.2019.02.008","volume":"29","author":"M G\u00e4rtner","year":"2019","unstructured":"G\u00e4rtner M, Aust S, Bajbouj M, Fan Y, Wingenfeld K, Otte C, et al. Functional connectivity between prefrontal cortex and subgenual cingulate predicts antidepressant effects of ketamine. Eur Neuropsychopharmacol. 2019;29:501\u20138. https:\/\/doi.org\/10.1016\/j.euroneuro.2019.02.008.","journal-title":"Eur Neuropsychopharmacol"},{"key":"3654_CR82","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.conb.2007.02.008","volume":"17","author":"M Sakagami","year":"2007","unstructured":"Sakagami M, Pan X. Functional role of the ventrolateral prefrontal cortex in decision making. Curr Opin Neurobiol. 2007;17:228\u201333. https:\/\/doi.org\/10.1016\/j.conb.2007.02.008.","journal-title":"Curr Opin Neurobiol"},{"key":"3654_CR83","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1038\/npp.2014.298","volume":"40","author":"JW Murrough","year":"2015","unstructured":"Murrough JW, Burdick KE, Levitch CF, Perez AM, Brallier JW, Chang LC, et al. Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial. Neuropsychopharmacology. 2015;40:1084\u201390. https:\/\/doi.org\/10.1038\/npp.2014.298.","journal-title":"Neuropsychopharmacology"},{"key":"3654_CR84","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-020-00945-9","volume":"10","author":"YL Zhou","year":"2020","unstructured":"Zhou YL, Wu FC, Liu WJ, Zheng W, Wang CY, Zhan YN, et al. Volumetric changes in subcortical structures following repeated ketamine treatment in patients with major depressive disorder: a longitudinal analysis. Transl Psychiatry. 2020;10:264. https:\/\/doi.org\/10.1038\/s41398-020-00945-9.","journal-title":"Transl Psychiatry"},{"key":"3654_CR85","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.jad.2020.06.068","volume":"276","author":"YL Zhou","year":"2020","unstructured":"Zhou YL, Wu FC, Wang CY, Zheng W, Lan XF, et al. Relationship between hippocampal volume and inflammatory markers following six infusions of ketamine in major depressive disorder. J Affect Disord. 2020;276:608\u201315. https:\/\/doi.org\/10.1016\/j.jad.2020.06.068.","journal-title":"J Affect Disord"},{"key":"3654_CR86","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.euroneuro.2020.01.017","volume":"33","author":"AK Sahib","year":"2020","unstructured":"Sahib AK, Loureiro JRA, Vasavada MM, Kubicki A, Joshi SH, Wang K, et al. Single and repeated ketamine treatment induces perfusion changes in sensory and limbic networks in major depressive disorder. Eur Neuropsychopharmacol. 2020;33:89\u2013100. https:\/\/doi.org\/10.1016\/j.euroneuro.2020.01.017.","journal-title":"Eur Neuropsychopharmacol"},{"key":"3654_CR87","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1017\/S0033291718001356","volume":"49","author":"F Palhano-Fontes","year":"2019","unstructured":"Palhano-Fontes F, Barreto D, Onias H, Andrade KC, Novaes MM, Pessoa JA, et al. Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial. Psychol Med. 2019;49:655\u201363. https:\/\/doi.org\/10.1017\/S0033291718001356.","journal-title":"Psychol Med"},{"key":"3654_CR88","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3389\/fnhum.2014.00020","volume":"8","author":"RL Carhart-Harris","year":"2014","unstructured":"Carhart-Harris RL, Leech R, Hellyer PJ, Shanahan M, Feilding A, Tagliazucchi E, et al. The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs. Front Hum Neurosci. 2014;8:20. https:\/\/doi.org\/10.3389\/fnhum.2014.00020.","journal-title":"Front Hum Neurosci"},{"key":"3654_CR89","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/jnc.15509","volume":"162","author":"U Kozlowska","year":"2022","unstructured":"Kozlowska U, Nichols C, Wiatr K, Figiel M. From psychiatry to neurology: psychedelics as prospective therapeutics for neurodegenerative disorders. J Neurochem. 2022;162:89\u2013108. https:\/\/doi.org\/10.1111\/jnc.15509.","journal-title":"J Neurochem"},{"key":"3654_CR90","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1192\/bjp.bp.113.129965","volume":"204","author":"NL Nixon","year":"2014","unstructured":"Nixon NL, Liddle PF, Nixon E, Worwood G, Liotti M, Palaniyappan L. Biological vulnerability to depression: linked structural and functional brain network findings. Br J Psychiatry. 2014;204:283\u20139. https:\/\/doi.org\/10.1192\/bjp.bp.113.129965.","journal-title":"Br J Psychiatry"},{"key":"3654_CR91","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1093\/scan\/nsu006","volume":"9","author":"V Zamoscik","year":"2014","unstructured":"Zamoscik V, Huffziger S, Ebner-Priemer U, Kuehner C, Kirsch P. Increased involvement of the parahippocampal gyri in a sad mood predicts future depressive symptoms. Soc Cogn Affect Neurosci. 2014;9:2034\u201340. https:\/\/doi.org\/10.1093\/scan\/nsu006.","journal-title":"Soc Cogn Affect Neurosci"},{"key":"3654_CR92","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1177\/02698811211073759","volume":"36","author":"N Gukasyan","year":"2022","unstructured":"Gukasyan N, Davis AK, Barrett FS, Cosimano MP, Sepeda ND, Johnson MW, et al. Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up. Journal Psychopharmacol (Oxf, Engl). 2022;36:151\u20138. https:\/\/doi.org\/10.1177\/02698811211073759.","journal-title":"Journal Psychopharmacol (Oxf, Engl)"},{"key":"3654_CR93","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1007\/s40263-022-00944-y","volume":"36","author":"N Pouyan","year":"2022","unstructured":"Pouyan N, Halvaei Khankahdani Z, Younesi Sisi F, Lee Y, Rosenblat JD, Teopiz KM, et al. A research domain criteria (RDoC)-guided dashboard to review psilocybin target domains: a systematic review. CNS Drugs. 2022;36:1031\u201347. https:\/\/doi.org\/10.1007\/s40263-022-00944-y.","journal-title":"CNS Drugs"},{"key":"3654_CR94","doi-asserted-by":"publisher","first-page":"e163","DOI":"10.1192\/bjo.2022.565","volume":"8","author":"T Barba","year":"2022","unstructured":"Barba T, Buehler S, Kettner H, Radu C, Cunha BG, Nutt DJ, et al. Effects of psilocybin versus escitalopram on rumination and thought suppression in depression. BJPsych Open. 2022;8:e163. https:\/\/doi.org\/10.1192\/bjo.2022.565.","journal-title":"BJPsych Open"},{"key":"3654_CR95","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1021\/acsptsci.1c00097","volume":"4","author":"JW Sanders","year":"2021","unstructured":"Sanders JW, Zijlmans J. Moving past mysticism in psychedelic science. ACS Pharmacol Transl Sci. 2021;4:1253\u20135. https:\/\/doi.org\/10.1021\/acsptsci.1c00097.","journal-title":"ACS Pharmacol Transl Sci"},{"key":"3654_CR96","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1021\/acsptsci.0c00194","volume":"4","author":"DB Yaden","year":"2021","unstructured":"Yaden DB, Griffiths RR. The subjective effects of psychedelics are necessary for their enduring therapeutic effects. ACS Pharmacol Transl Sci. 2021;4:568\u201372. https:\/\/doi.org\/10.1021\/acsptsci.0c00194.","journal-title":"ACS Pharmacol Transl Sci"},{"key":"3654_CR97","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s00213-017-4733-3","volume":"235","author":"Y Schmid","year":"2018","unstructured":"Schmid Y, Liechti ME. Long-lasting subjective effects of LSD in normal subjects. Psychopharmacology (Berl). 2018;235:535\u201345. https:\/\/doi.org\/10.1007\/s00213-017-4733-3.","journal-title":"Psychopharmacology (Berl)"},{"key":"3654_CR98","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1111\/cns.13230","volume":"25","author":"MC Spano","year":"2019","unstructured":"Spano MC, Lorusso M, Pettorruso M, Zoratto F, Di Giuda D, Martinotti G, et al. Anhedonia across borders: transdiagnostic relevance of reward dysfunction for noninvasive brain stimulation endophenotypes. CNS Neurosci Ther. 2019;25:1229\u201336. https:\/\/doi.org\/10.1111\/cns.13230.","journal-title":"CNS Neurosci Ther"},{"key":"3654_CR99","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1146\/annurev-clinpsy-050212-185606","volume":"10","author":"DA Pizzagalli","year":"2014","unstructured":"Pizzagalli DA. Depression, stress, and anhedonia: toward a synthesis and integrated model. Annu Rev Clin Psychol. 2014;10:393\u2013423. https:\/\/doi.org\/10.1146\/annurev-clinpsy-050212-185606.","journal-title":"Annu Rev Clin Psychol"},{"key":"3654_CR100","doi-asserted-by":"publisher","first-page":"112548","DOI":"10.1016\/j.bbr.2020.112548","volume":"384","author":"SS Kokane","year":"2020","unstructured":"Kokane SS, Armant RJ, Bola\u00f1os-Guzm\u00e1n CA, Perrotti LI. Overlap in the neural circuitry and molecular mechanisms underlying ketamine abuse and its use as an antidepressant. Behav Brain Res. 2020;384:112548. https:\/\/doi.org\/10.1016\/j.bbr.2020.112548.","journal-title":"Behav Brain Res"},{"key":"3654_CR101","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.jad.2023.12.038","volume":"348","author":"G d\u2019Andrea","year":"2024","unstructured":"d\u2019Andrea G, Pettorruso M, Di Lorenzo G, Rhee TG, Chiappini S, Carullo R, et al. The rapid antidepressant effectiveness of repeated dose of intravenous ketamine and intranasal esketamine: a post-hoc analysis of pooled real-world data. J Affect Disord. 2024;348:314\u201322. https:\/\/doi.org\/10.1016\/j.jad.2023.12.038.","journal-title":"J Affect Disord"},{"key":"3654_CR102","doi-asserted-by":"publisher","first-page":"109299","DOI":"10.1016\/j.neuropharm.2022.109299","volume":"223","author":"MY Jawad","year":"2023","unstructured":"Jawad MY, Di Vincenzo JD, Badulescu S, Teopiz KM, Tabassum A, Ceban F, et al. The therapeutic role of ketamine and esketamine in treating psychopathological domains of depression. Neuropharmacology. 2023;223:109299. https:\/\/doi.org\/10.1016\/j.neuropharm.2022.109299.","journal-title":"Neuropharmacology"},{"key":"3654_CR103","doi-asserted-by":"publisher","first-page":"820","DOI":"10.3389\/fpsyt.2020.00820","volume":"11","author":"M Thai","year":"2020","unstructured":"Thai M, Ba\u015fg\u00f6ze Z, Klimes-Dougan B, Mueller BA, Fiecas M, Lim KO, et al. Neural and behavioral correlates of clinical improvement to ketamine in adolescents with treatment resistant depression. Front Psychiatry. 2020;11:820. https:\/\/doi.org\/10.3389\/fpsyt.2020.00820.","journal-title":"Front Psychiatry"},{"key":"3654_CR104","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1177\/02698811221140004","volume":"37","author":"JE Henningfield","year":"2023","unstructured":"Henningfield JE, Ashworth J, Heal DJ, Smith SL. Psychedelic drug abuse potential assessment for new drug applications and controlled substance scheduling: A United States perspective. J Psychopharmacol. 2023;37:33\u201344. https:\/\/doi.org\/10.1177\/02698811221140004.","journal-title":"J Psychopharmacol"},{"key":"3654_CR105","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.jpsychires.2022.04.035","volume":"151","author":"TT Le","year":"2022","unstructured":"Le TT, Cordero IP, Jawad MY, Swainson J, Di Vincenzo JD, Jaberi S, et al. The abuse liability of ketamine: a scoping review of preclinical and clinical studies. J Psychiatr Res. 2022;151:476\u201396. https:\/\/doi.org\/10.1016\/j.jpsychires.2022.04.035.","journal-title":"J Psychiatr Res"},{"key":"3654_CR106","doi-asserted-by":"publisher","first-page":"114231","DOI":"10.1016\/j.psychres.2021.114231","volume":"306","author":"TT Le","year":"2021","unstructured":"Le TT, Di Vincenzo JD, Teopiz KM, Lee Y, Cha DS, Lui LMW, et al. Ketamine for psychotic depression: An overview of the glutamatergic system and ketamine\u2019s mechanisms associated with antidepressant and psychotomimetic effects. Psychiatry Res. 2021;306:114231. https:\/\/doi.org\/10.1016\/j.psychres.2021.114231.","journal-title":"Psychiatry Res"}],"container-title":["Translational Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41398-025-03654-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-025-03654-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-025-03654-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:31:52Z","timestamp":1761895912000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41398-025-03654-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,31]]},"references-count":106,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3654"],"URL":"https:\/\/doi.org\/10.1038\/s41398-025-03654-3","relation":{},"ISSN":["2158-3188"],"issn-type":[{"value":"2158-3188","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,31]]},"assertion":[{"value":"22 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"GM has been a consultant and\/or a speaker and\/or has received research grants from Angelini, Doc Generici, Janssen-Cilag, Lundbeck, Otsuka, Pfizer, Servier and Recordati. SC, MP, AM, A Mi, FDC, GDA, LC, FMS, RT, FM, and DDB have nothing to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"453"}}